It is estimated than more than 10.000 people were affected by their mothers using thalidomide during their pregnancy; about forty percent of the children died at birth or shortly afterwards. Those who survived had limb, eye, urinary tract, and heart defects. Its initial entry into the US market was prevented by Frances Kelsey at the FDA. The birth defects of thalidomide led to the development of greater drug regulation and monitoring in many countries.